H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The ...
While Moderna Inc. plans to cut its expenses by $1 billion in 2025, the company has received a little breathing room by a hefty U.S. Department of Health and Human Services (HHS) grant. The Biomedical ...
today announced the company won the Biomedical Advanced Research and Development Authority (BARDA) Patch Forward competition and presented at an event during the J.P. Morgan Healthcare Conference ...
Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, has been named a C ...
Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The ...
proudly announces its selection as a Concept Stage winner in the prestigious United States Biomedical Advanced Research and Development Authority (BARDA) Patch Forward Prize. Achieved in ...
Micron Biomedical, a life science company developing the world’s first needle-free technology for drugs and vaccines that is based on dissolvable microarrays, ...